Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234550 | 1.00 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL4619337 | 0.98 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL16180769 | 0.98 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5330004 | 0.90 | ESR1 (0.36) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4744273 | 0.86 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL1443600 | 0.85 | CYP2A6 (0.35) | TDP1 | |
| SCHEMBL900597 | 0.82 | — | — | |
| SCHEMBL1460886 | 0.82 | CYP2A6 (0.35) | CYP3A4TDP1 | |
| SCHEMBL3632076 | 0.81 | HSD17B2 (0.33) | — | |
| SCHEMBL8913546 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658557-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3658557-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-2569275-A1 | A PROCESS FOR THE HYDROGENATION OF KETOESTERS | Lonza Ltd. (CH) | 2013-03-20 | — | — | EP | disclosed |
| CN-102971285-A | A process for the production of carnitine | LONZA AG | 2013-03-13 | — | — | CN | disclosed |
| CN-102844293-A | A process for the hydrogenation of ketoesters | LONZA AG | 2012-12-26 | — | — | CN | disclosed |
| US-20120022275-A1 | PROCESS FOR THE PRODUCTION OF CARNITINE BY CYCLOADDITION | LONZA LTD. (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010296-A1 | A PROCESS FOR THE PRODUCTION OF CARNITINE | LONZA LTD (CH) | 2012-01-26 | — | — | WO | disclosed |
| EP-2409965-A1 | A process for the production of carnitine by cycloaddition | Lonza Ltd. (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20120016153-A1 | PROCESS FOR THE HYDROGENATION OF KETOESTERS | LONZA LTD (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2011141160-A1 | A PROCESS FOR THE HYDROGENATION OF KETOESTERS | LONZA LTD (CH) | 2011-11-17 | — | — | WO | disclosed |
| EP-2386536-A1 | A process for the hydrogenation of ketoesters | Lonza Ltd. (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8037666-B2 | Mower with an lightening device including torsion bars | KUHN S.A. (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP3A4 4404/4885TDP1 330/4885ESR1 3159/4885 |
| US-20120016153-A1 | PROCESS FOR THE HYDROGENATION OF KETOESTERS | CBR3, BCKDK, PAOX | CYP3A4 23/4885TDP1 4284/4885ESR1 2813/4885 |
| US-20120022275-A1 | PROCESS FOR THE PRODUCTION OF CARNITINE BY CYCLOADDITION | CRAT, CPT2, CPT1B | CYP3A4 754/4885TDP1 4709/4885ESR1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.